• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在肯尼亚，接受司他夫定与齐多夫定为基础的抗逆转录病毒治疗方案的成年人中，出现症状性周围神经病的发病率增加。

Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.

机构信息

Department of Global Health, University of Washington, Seattle, WA 98104-2499, USA.

出版信息

J Neurovirol. 2012 Jun;18(3):200-4. doi: 10.1007/s13365-012-0098-x. Epub 2012 Apr 17.

DOI:10.1007/s13365-012-0098-x
PMID:22528481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3726537/
Abstract

The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described. We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4T-based and 269 (15 %) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n=236) among d4T users and 6.9 (n=7) among ZDV users (P=0.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P=0.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.

摘要

开始使用含司他夫定（d4T）或齐多夫定（ZDV）的抗逆转录病毒疗法（ART）的成年人中周围神经病变（PN）的发生率尚未很好地描述。我们比较了在肯尼亚一个规划环境中开始 ART 的成年人中，基于 d4T 和 ZDV 的方案在一年内的发生率。在 1848 名接受 ART 的成年人中，1579 名（85%）开始使用 d4T 为基础的方案，269 名（15%）开始使用 ZDV 为基础的方案。d4T 使用者中每 100 人年发生症状性 PN 的发生率为 21.9（n=236），ZDV 使用者为 6.9（n=7）（P=0.0002）。d4T 发生 PN 的风险比 ZDV 高 2.7 倍（调整后的危险比，2.7，P=0.009）。在继续使用 d4T 的环境中，例如非洲，在选择 ART 方案时，应考虑 d4T 与 ZDV 相比对 PN 的影响。

相似文献

1
Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.在肯尼亚，接受司他夫定与齐多夫定为基础的抗逆转录病毒治疗方案的成年人中，出现症状性周围神经病的发病率增加。
J Neurovirol. 2012 Jun;18(3):200-4. doi: 10.1007/s13365-012-0098-x. Epub 2012 Apr 17.
2
An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.齐多夫定加拉米夫定与司他夫定加拉米夫定的开放性随机对照试验。
AIDS. 1998 Aug 20;12(12):1513-9. doi: 10.1097/00002030-199812000-00014.
3
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.一项关于将司他夫定或齐多夫定换用为富马酸替诺福韦二吡呋酯对病毒学得到抑制的HIV-1感染儿童安全性和疗效的随机、开放标签研究。
Pediatr Infect Dis J. 2015 Apr;34(4):376-82. doi: 10.1097/INF.0000000000000289.
4
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).在未接受过抗逆转录病毒治疗的HIV感染者中，司他夫定加拉米夫定与齐多夫定加拉米夫定联合茚地那韦的比较：胸腺嘧啶核苷类似物治疗方案的选择（START I）
AIDS. 2000 Jul 28;14(11):1591-600. doi: 10.1097/00002030-200007280-00015.
5
A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.司他夫定（d4T）与齐多夫定（ZDV，AZT）治疗儿童人类免疫缺陷病毒感染的随机对照试验。艾滋病临床试验组240团队。
Pediatrics. 1998 Feb;101(2):214-20. doi: 10.1542/peds.101.2.214.
6
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.对接受含司他夫定和齐多夫定治疗方案且出现脂肪萎缩的HIV患者进行脂肪因子表达和线粒体毒性评估。
J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72. doi: 10.1097/01.qai.0000187443.30838.3e.
7
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.在南非，一项比较 4 种治疗方案的随机析因试验，该试验纳入了未经治的 HIV 感染合并 AIDS 和/或 CD4 细胞计数＜200 个/μL 的患者。
J Infect Dis. 2010 Nov 15;202(10):1529-37. doi: 10.1086/656718. Epub 2010 Oct 13.
8
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).司他夫定、去羟肌苷和茚地那韦与齐多夫定、拉米夫定和茚地那韦用于初始治疗HIV-1感染个体的比较：胸苷类似物方案疗法的选择（START II）
AIDS. 2000 Jul 28;14(11):1601-10. doi: 10.1097/00002030-200007280-00016.
9
The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients.在从未接受过齐多夫定治疗、有抗逆转录病毒治疗经验的HIV-1感染患者中，齐多夫定敏感性降低的患病率。
HIV Med. 2003 Oct;4(4):305-10. doi: 10.1046/j.1468-1293.2003.00163.x.
10
Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens.乌干达一组接受含齐多夫定、司他夫定和替诺福韦抗逆转录病毒治疗方案的HIV感染成人中严重贫血的发生情况及血红蛋白变化
J Int Assoc Provid AIDS Care. 2015 Sep-Oct;14(5):455-62. doi: 10.1177/2325957414557264. Epub 2014 Nov 25.

引用本文的文献

1
Neurological disorders in HIV in Africa: a review.非洲地区HIV相关神经系统疾病综述
Afr Health Sci. 2019 Jun;19(2):1953-1977. doi: 10.4314/ahs.v19i2.19.
2
Predictors of dropout from care among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment clinic in sub-Saharan Africa.撒哈拉以南非洲一家公共部门艾滋病毒治疗诊所中开始接受抗逆转录病毒治疗的艾滋病毒感染患者护理中断的预测因素。
BMC Infect Dis. 2016 Feb 1;16:43. doi: 10.1186/s12879-016-1392-7.
3
Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy.开始接受治疗的泰国HIV感染者的表皮神经纤维密度、氧化应激和线粒体单倍群
AIDS. 2014 Jul 17;28(11):1625-33. doi: 10.1097/QAD.0000000000000297.
4
Neurological and psychiatric adverse effects of antiretroviral drugs.抗反转录病毒药物的神经和精神不良反应。
CNS Drugs. 2014 Feb;28(2):131-45. doi: 10.1007/s40263-013-0132-4.
5
Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.南非城区诊所中与依从性措施无关的一线病毒学失败的早期预警指标。
AIDS Patient Care STDS. 2013 Dec;27(12):657-68. doi: 10.1089/apc.2013.0263.
6
HIV-related neuropathy: current perspectives.与人类免疫缺陷病毒相关的神经病变：当前观点
HIV AIDS (Auckl). 2013 Sep 11;5:243-51. doi: 10.2147/HIV.S36674.

本文引用的文献

1
Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.南非成人HIV感染者一线治疗随机试验中的乳酸酸中毒和症状性高乳酸血症
Antivir Ther. 2011;16(4):605-9. doi: 10.3851/IMP1790.
2
HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans.南非达芦那韦暴露人群的 HIV 神经病变危险因素和症状特征。
J Pain Symptom Manage. 2011 Apr;41(4):700-6. doi: 10.1016/j.jpainsymman.2010.07.006. Epub 2010 Dec 8.
3
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.在乌干达，接受一线抗逆转录病毒治疗的成年患者 3 年前瞻性队列研究中，司他夫定毒性是导致女性治疗方案改变的主要原因。
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):59-63. doi: 10.1097/QAI.0b013e3181f5bd03.
4
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.在联合抗逆转录病毒治疗时代，人类免疫缺陷病毒相关感觉神经病变的持续高患病率及不良临床影响：CHARTER研究
Arch Neurol. 2010 May;67(5):552-8. doi: 10.1001/archneurol.2010.76.
5
Age and height predict neuropathy risk in patients with HIV prescribed stavudine.年龄和身高可预测接受司他夫定治疗的HIV患者发生神经病变的风险。
Neurology. 2009 Jul 28;73(4):315-20. doi: 10.1212/WNL.0b013e3181af7a22.
6
Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program.先前接受高效抗逆转录病毒治疗（HAART）对肯尼亚一项大型艾滋病治疗项目临床结果的影响。
Curr HIV Res. 2009 Jul;7(4):441-6. doi: 10.2174/157016209788680552.
7
Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.司他夫定治疗乌干达HIV相关神经并发症的益处与风险
Neurology. 2009 Jan 13;72(2):165-70. doi: 10.1212/01.wnl.0000339042.96109.86.
8
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.在喀麦隆，奈韦拉平与拉米夫定联合齐多夫定或司他夫定的一线治疗方案的耐受性和有效性。
AIDS Res Hum Retroviruses. 2008 Mar;24(3):393-9. doi: 10.1089/aid.2007.0219.
9
Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial.博茨瓦纳接受高效抗逆转录病毒治疗的女性中乳酸酸中毒发生率高于预期：一项大型随机临床试验的初步结果。
J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):318-22. doi: 10.1097/QAI.0b013e3181568e3f.
10
Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency.在CD4细胞计数≥350个细胞/立方毫米时开始抗逆转录病毒治疗不会增加周围神经病变、贫血或肾功能不全的发生率或风险。
J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):27-35. doi: 10.1097/QAI.0b013e31815acacc.